Komen Northwest Ohio Homepage

FDA approves new treatment for late-stage breast cancer
On Friday, February 22nd, the U.S. Food and Drug Administration approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer..
More

Mammogram Screening Days
Click here for a list of upcoming mammogram screening days..
More

Important Flu Information for Breast Cancer Survivors
The Centers for Disease Control and Prevention (CDC) recommends everyone aged six and older, including breast cancer survivors and their caregivers, receive the seasonal flu shot. People currently undergoing treatment for breast cancer and long-term survivors are at higher risk for complications from the seasonal flu..
More

2 RACES. 2 CITIES. 2 DAYS.

We've added a second Race! Race for the Cure is coming to Findlay, Ohio on Saturday, September 28, 2013! Click here to fill out a volunteer application if you are interested in being on the Findlay Race committee or volunteering on Race day! And mark your calendar for Sunday, September 29, 2013 for the 20th Annual Komen Race for the Cure in Downtown Toledo! Online registration for both Races is now open!

Now Announcing 20 Weeks of Giveaways!

In honor of 20 weeks until Race weekend we are announcing our 20 Weeks of Giveaways promotion! We challenge you to ask 20 friends to donate $20 to Race for the Cure! Start Fundraising TODAY and get the chance to win one of these many great prizes! All Race participants raising $400 or more will also be entered to win a GRAND PRIZE valued at $2,000! For every $400 raised you will receive an additional entry so the sky is the limit!

Is ductal carcinoma in situ (DCIS) breast cancer?
Ductal carcinoma in situ (DCIS) is breast cancer, but it is non-invasive. About 55,000 new cases of DCIS are expected to be diagnosed among women in the U.S. in 2013. Learn more now.

How Komen's research investment has changed the breast cancer landscape
As we've come to understand more about the biology of breast cancer, Komen's research agenda has changed tremendously over the past 10-15 years. Read more about Komen's research investment.